XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Equity (USD $)
Total
Cash And Services
Charitable contribution
Series C Preferred Stock
Series E Preferred Stock
PCT Merger
Amorcyte Merger
Series B Convertible Preferred Stock
Common Stock
Common Stock
Cash And Services
Common Stock
Charitable contribution
Common Stock
PCT Merger
Common Stock
Amorcyte Merger
Additional Paid in Capital
Additional Paid in Capital
Cash And Services
Additional Paid in Capital
Charitable contribution
Additional Paid in Capital
PCT Merger
Additional Paid in Capital
Amorcyte Merger
Accumulated Other Comprehensive Income
Accumulated Deficit
Accumulated Deficit
Series C Preferred Stock
Accumulated Deficit
Series E Preferred Stock
Total NeoStem, Inc. Shareholders' Equity
Total NeoStem, Inc. Shareholders' Equity
Cash And Services
Total NeoStem, Inc. Shareholders' Equity
Charitable contribution
Total NeoStem, Inc. Shareholders' Equity
Series C Preferred Stock
Total NeoStem, Inc. Shareholders' Equity
Series E Preferred Stock
Total NeoStem, Inc. Shareholders' Equity
PCT Merger
Total NeoStem, Inc. Shareholders' Equity
Amorcyte Merger
Non-Controlling Interest in Subsidiaries
Beginning Balance at Dec. 31, 2009 $ 57,832,377             $ 100 $ 37,193         $ 95,709,491         $ (56,504) $ (71,776,951)     $ 23,913,329             $ 33,919,048
Beginning Balance (in shares) at Dec. 31, 2009               10,000 37,193,491                                          
Comprehensive income (loss):                                                            
Net income (loss) (19,397,016)                                     (23,305,706)     (23,305,706)             3,908,690
Foreign currency translation 2,835,570                                   2,835,570       2,835,570              
Total comprehensive income (loss) (16,561,446)                                           (20,470,136)             3,908,690
Exercise of stock options (in shares)                 90,000                                          
Exercise of stock options 140,100               90         140,010                 140,100              
Exercise of warrants (in shares)                 2,025,000                                          
Exercise of warrants 2,961,750               2,025         2,959,725                 2,961,750              
Share-based compensation (in shares)                 349,517                                          
Share-based compensation 7,564,993               350         7,564,643                 7,564,993              
Shares issued (in shares)                   15,326,998 150,000                                      
Shares issued   21,425,538 298,500             15,327 150       21,410,211 298,350               21,425,538 298,500          
Conversion of Series C Preferred (in shares)                 9,086,124                                          
Conversion of Series C Preferred 13,720,048               9,086         13,710,962                 13,720,048              
Receipt of treasury shares (656,278)               (408)         (655,870)                 (656,278)              
Dividends on Preferred       (153,469) (84,494)                               (153,469) (84,494)       (153,469) (84,494)      
Ending Balance at Dec. 31, 2010 86,487,619             100 63,813         141,137,522         2,779,066 (95,320,620)     48,659,881             37,827,738
Ending Balance (in shares) at Dec. 31, 2010               10,000 64,221,130                                          
Comprehensive income (loss):                                                            
Net income (loss) (56,582,857)                                     (47,134,469)     (47,134,469)             (9,448,388)
Foreign currency translation 2,596,987                                   1,373,277       1,373,277             1,223,710
Total comprehensive income (loss) (53,985,870)                                           (45,761,192)             (8,224,678)
Exercise of stock options (in shares)                 5,000                                          
Exercise of stock options 7,100               5         7,095                 7,100              
Share-based compensation (in shares)                 3,824,018                                          
Share-based compensation 10,266,023               3,824         10,262,199                 10,266,023              
Shares issued (in shares)                   19,678,224                                        
Shares issued   21,152,682 607,363             19,678 408       21,133,004 606,955               21,152,682 607,363          
Repayment of Series E Preferred Principal and Dividends (in shares)                 5,157,732                                          
Repayment of Series E Preferred Principal and Dividends 3,620,300               5,158         4,254,907           (639,765)     3,620,300              
Dividends to related party (11,726,099)                                                         (11,726,099)
Technology contributed to Athelos by Non-Controlling Interest 1,150,000                         920,000                 920,000             230,000
Shares issued in Merger (in shares)                       10,600,000 5,843,483                                  
Shares issued in Merger           17,200,000 5,353,400         10,600 5,844       17,189,400 5,347,556                   17,200,000 5,353,400  
Ending Balance at Dec. 31, 2011 $ 80,132,518             $ 100 $ 109,330         $ 200,858,638         $ 4,152,343 $ (143,094,854)     $ 62,025,557             $ 18,106,961
Ending Balance (in shares) at Dec. 31, 2011               10,000 109,329,587